viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals co-founder to present on latest achievements at Proactive cannabis webinar

The webinar will also be live-streamed on the Proactive YouTube channel, which can then be viewed at any time following the presentation.

MGC Pharmaceuticals Ltd - MGC Pharmaceuticals co-founder to present on latest achievements at Proactive cannabis webinar
MGC Pharmaceuticals is a European-based biopharma company

MGC Pharmaceuticals Ltd (ASX:MXC) co-founder and MD Roby Zamer is set to present on its achievements including the latest pre-clinical in-vitro laboratory results at Proactive cannabis webinar on Tuesday, August 11.

The company's shares surged 41% this morning after the results confirmed the effective immunological activity for the use of ArtemiC as an immune-modulatory agent for the treatment of COVID-19.

Further studies are underway and planned to augment these initial findings to evaluate the preferable ratios between the active ingredients.

MGC is currently awaiting the first interim results from the COVID-19 infected patients from the Phase II randomised, double-blind clinical trial underway in Israel, which are expected to be finalised shortly.

Co-founder and MD Roby Zamer 

Two leading cannabinoid medicinal products

The European-based bio pharma company creates premium phytocannabinoid-based products from its GMP facility in Europe that can be used to treat patients suffering from a variety of symptomatic conditions.

The company has two leading cannabinoid medicinal products in late-stage development - CannEpil®, an oral oil solution treatment for refractory epilepsy and CogniCann®, an oral spray for relief of dementia symptoms.

With facilities in Australia, Slovenia and the Czech Republic, MGC Pharma’s mission is to build an innovative company that provides affordable phytocannabinoid medicines for targeted global markets and patients.

Three companies to present

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins will present on the company’s access to the world largest and fastest growing cannabis markets and Southern Cannabis Holdings director and CEO Tim Drury is set to highlight the ways the company operates high-value brands across the cannabis value chain.

Event details

  • Date – Tuesday, August 4
  • Time – 12PM Sydney time / 10am Perth time
  • To register – please follow this link
  • Questions can be submitted to John Phillips at john.phillips@proactiveinvestors.com 

Quick facts: MGC Pharmaceuticals Ltd


Price: 3.39 GBX

Market Cap: £80.84 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


MGC Pharmaceuticals: Continuous global breakthroughs as progress accelerates

Proactive Research Analyst Ed Stacey presents his analysis on MGC Pharmaceuticals (LON:MXC).  The company recently announced that it has received a UK import permit for CannEpil+, which is MGC’s cannabis-derived therapy for refractory epilepsy, to be used initially on a compassionate access...

3 days, 11 hours ago

2 min read